Contineum Therapeutics Inc Class A Common Stock CTNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTNM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $14.96
- Day Range
- $14.75–15.66
- 52-Week Range
- $13.27–16.09
- Bid/Ask
- $15.02 / $15.61
- Market Cap
- $389.53 Mil
- Volume/Avg
- 63,002 / 127,456
Key Statistics
- Price/Earnings (Normalized)
- 14.28
- Price/Sales
- 6.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.contineum-tx.com
Valuation
|
Metric
|
CTNM
|
|---|---|
Price/Earnings (Normalized) | 14.28 |
Price/Book Value | — |
Price/Sales | 6.31 |
Price/Cash Flow | 19.29 |
Price/Earnings
CTNM
Financial Strength
|
Metric
|
CTNM
|
|---|---|
Quick Ratio | 18.91 |
Current Ratio | 19.20 |
Interest Coverage | 119.41 |
Quick Ratio
CTNM
Profitability
|
Metric
|
CTNM
|
|---|---|
Return on Assets (Normalized) | 14.40% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CTNM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nkwnmlbl | Rdhy | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pxmdbhtpd | Bpncjzh | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xvpxnzs | Hjwvgy | $108.2 Bil | |
MRNA
| Moderna Inc | Zsstvvbd | Hfqrp | $50.9 Bil | |
ARGX
| argenx SE ADR | Fmtnmnqzt | Shngy | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Wmnmhzvf | Ljvy | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zchbhkqqv | Xkstfr | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tbyjjlxb | Dlxdwsn | $14.6 Bil | |
INCY
| Incyte Corp | Vctgwfkw | Qlctr | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bkgqsvxyz | Jhnrwyc | $12.3 Bil |